Page 87 - CIBEREHD2016-ENG

Most relevant scientific articles
• Pauta M., Rotllan N., Fernandez-Hernando A., Langhi C., Ribera J., Lu M. et al. Akt-mediated foxo1 inhibition is required for liver regeneration. Hepatology. 2016.
• Fernandez-Varo G., Oro D., Cable E.E., Reichenbach V., Carvajal S., de la Presa B.G. et al. Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats. Hepatology. 2016;63(1):207-216.
• Claria J., Stauber R.E., Coenraad M.J., Moreau R., Jalan R., Pavesi M. et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatology. 2016;64(4):1249-1264.
• Ariza X., Graupera I., Coll M., Sola E., Barreto R., Garcia E. et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. Journal of Hepatology. 2016.
• Huelin P., Piano S., Sola E., Stanco M., Sole C., Moreira R. et al. Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure. Clinical Gastroenterology and Hepatology. 2016.
Hightlights
The group’s clinical and translational research has described new biomarkers to evaluate the progression of cirrosis and the development of ACLF, of these NGAL is the most promising. We have also described the role of systemic inflammation and molecular pathways of liver injury in the pathophysiology of cirrhosis progression. The clinical investigation has led to the validation of a new classification of AKI.
We have provided solid evidence that systemic inflammation, and the cytokine storm in particular, is the main driver of Acute-on-Chronic Liver Failure in patients with decompensated cirrhosis. In addition, we have unveiled the mechanisms by which specialized pro-resolving lipid mediators modulate the cell signaling of the anti-inflammatory cytokine IL-10, and thus promote the resolution of inflammation in visceral adipose tissue from obese individuals at risk of developing non-alcoholic fatty liver disease.
PROJECTS
• Jiménez W and Fernández-Varo G. Utilidad terapéutica de las nanopartículas de óxido de cerio en las enfermedades hepáticas. Sponsored by MINECO/SAF15-64126-R. Duration: 1/1/2016-31/12/2018.
• Morales-Ruiz M. Potencialidad terapéutica del fosfoproteoma de Akt/PKB en la regeneración hepática y en la cirrosis. Sponsored by MINECO/SAF13-41840-R. Duration: 1/1/2014-31/5/2017.
• Casals G. Evaluación de las propiedades antioxidantes y antiinflamatorias de las nanopartículas de óxido de cerio como nueva estrategia terapéutica en la esteatosis hepática. Sponsored by MINECO/ PI15/00777. Duration: 1/1/2016-31/12/2018
• Finally, during 2016 has led the design of a new European Horizon 2020 Project, aimed at evaluating the utility of combined rifaximin and statin therapy to prevent the progression of Cirrhosis.
EUROPEAN PATENT
Jiménez W, Puntes VF and Fernández-Varo G. Ceria nanoparticles for use in the treatment of hepatocellular carcinoma. Application number: EP16163838.2. Date: 5/4/2016.
EHD
research Groups 87